Compared side by side
PT-141 vs setmelanotide: how they differ
The short answer
Both are melanocortin receptor agonists that act in the brain, for different jobs: PT-141 acts mainly on MC4R and MC1R to raise sexual desire and arousal, and setmelanotide, built on α-MSH, acts on the MC4 receptor of the hunger pathway where that pathway is broken upstream. Both are FDA-approved: PT-141 as Vyleesi, taken as needed for low sexual desire in premenopausal women, and setmelanotide as Imcivree, a daily shot for rare kinds of obesity such as Bardet-Biedl syndrome or a POMC, PCSK1 or LEPR gene variant. Both can darken the skin: PT-141 with frequent use, and setmelanotide through its weaker action on the MC1 receptor of pigment cells.
Side by side
| Compared | PT-141 | Setmelanotide |
|---|---|---|
| Category | Sexual health | Metabolic & GLP-1 |
| Also known as | Bremelanotide, PT141, Vyleesi | Imcivree, RM-493, BIM-22493 |
| What it is | An FDA-approved, as-needed treatment for low sexual desire in premenopausal women that acts through brain melanocortin receptors rather than blood flow (flibanserin/Addyi is the other, daily option). | A daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant. |
| How it works | Melanocortin receptor agonist (mainly MC4R and MC1R at the approved dose) that acts in the brain to increase sexual desire and arousal; the label says the exact mechanism is unknown. Doesn't work by increasing genital blood flow like PDE5 inhibitors (Viagra etc.), though it can briefly raise blood pressure. FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women. | A melanocortin-4 (MC4) receptor agonist: an 8-amino-acid ring-shaped peptide built on α-MSH, the body's own signal on the brain's hunger and satiety pathway. Where that pathway is broken upstream of the MC4 receptor (a hypothalamic injury or tumour, Bardet-Biedl syndrome, or a POMC, PCSK1 or LEPR gene variant), it is thought to restore the signal, lowering hunger and food intake and raising energy use. It also acts, about 20-fold more weakly, on the MC1 receptor of pigment cells, which is why the skin darkens. FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026. The label says it is not expected to work in common (polygenic) obesity. |
| Commonly reported | A noticeable rise in desire and arousal an hour or so after dosing (men often describe firmer or spontaneous erections), nausea that is often worst with the first dose, facial flushing, and headache on dosing days. Frequent use can cause skin darkening. | Less hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020. |
| Studied range | Research range: 0.5–2 mg, starting dose 1.25 mg. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD). | FDA label: 0.5–3 mg, starting dose 0.5 mg. |
| How often | As needed, 1–2 hours before | Daily SubQ |
| Half-life | ~2.7 hours (FDA label; range 1.9–4.0 hours) | ~11 hours (FDA label) |
| Route | SubQ injection | SubQ injection |
| Typical run | As-needed use. Daily use leads to hyperpigmentation — limit frequency. | FDA-approved for long-term use ("reduce excess body weight and maintain weight reduction long term"); its trials ran 52 to 66 weeks. In the gene-variant trials, weight came back during a 4-week placebo withdrawal and fell again on restarting. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use | Skin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections |
- Category
- PT-141Sexual health
- SetmelanotideMetabolic & GLP-1
- Also known as
- PT-141Bremelanotide, PT141, Vyleesi
- SetmelanotideImcivree, RM-493, BIM-22493
- What it is
- PT-141An FDA-approved, as-needed treatment for low sexual desire in premenopausal women that acts through brain melanocortin receptors rather than blood flow (flibanserin/Addyi is the other, daily option).
- SetmelanotideA daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant.
- How it works
- PT-141Melanocortin receptor agonist (mainly MC4R and MC1R at the approved dose) that acts in the brain to increase sexual desire and arousal; the label says the exact mechanism is unknown. Doesn't work by increasing genital blood flow like PDE5 inhibitors (Viagra etc.), though it can briefly raise blood pressure. FDA-approved as Vyleesi (2019) for acquired, generalized HSDD in premenopausal women.
- SetmelanotideA melanocortin-4 (MC4) receptor agonist: an 8-amino-acid ring-shaped peptide built on α-MSH, the body's own signal on the brain's hunger and satiety pathway. Where that pathway is broken upstream of the MC4 receptor (a hypothalamic injury or tumour, Bardet-Biedl syndrome, or a POMC, PCSK1 or LEPR gene variant), it is thought to restore the signal, lowering hunger and food intake and raising energy use. It also acts, about 20-fold more weakly, on the MC1 receptor of pigment cells, which is why the skin darkens. FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026. The label says it is not expected to work in common (polygenic) obesity.
- Commonly reported
- PT-141A noticeable rise in desire and arousal an hour or so after dosing (men often describe firmer or spontaneous erections), nausea that is often worst with the first dose, facial flushing, and headache on dosing days. Frequent use can cause skin darkening.
- SetmelanotideLess hunger within weeks, skin and moles darkening, and nausea at the start. FDA-approved since 2020.
- Studied range
- PT-141Research range: 0.5–2 mg, starting dose 1.25 mg. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD).
- SetmelanotideFDA label: 0.5–3 mg, starting dose 0.5 mg.
- How often
- PT-141As needed, 1–2 hours before
- SetmelanotideDaily SubQ
- Half-life
- PT-141~2.7 hours (FDA label; range 1.9–4.0 hours)
- Setmelanotide~11 hours (FDA label)
- Route
- PT-141SubQ injection
- SetmelanotideSubQ injection
- Typical run
- PT-141As-needed use. Daily use leads to hyperpigmentation — limit frequency.
- SetmelanotideFDA-approved for long-term use ("reduce excess body weight and maintain weight reduction long term"); its trials ran 52 to 66 weeks. In the gene-variant trials, weight came back during a 4-week placebo withdrawal and fell again on restarting.
- Evidence
- PT-141Established: clinical trials or FDA-approved use exists
- SetmelanotideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- PT-141Nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use
- SetmelanotideSkin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
PT-141
- Day 1–1 First dose — give it 45 minutes
- Day 1–7 Nausea fades with experience
- Day 1–1 Timing and dose are the two dials that matter
Setmelanotide
- Day 1–14 · 0.5 mg The 0.5 mg start
- Day 1–14 · 2 mg The 2 mg start
- Day 14–90 Why the skin darkens
- Day 15–365 · 3 mg 3 mg, the maintenance dose
Questions people ask
How long do PT-141 and setmelanotide last?
The half-life of PT-141 is ~2.7 hours (FDA label; range 1.9–4.0 hours). The half-life of setmelanotide is ~11 hours (FDA label).
How often are PT-141 and setmelanotide taken?
PT-141: as needed, 1–2 hours before. Route: SubQ injection. Setmelanotide: daily SubQ. Route: SubQ injection.
How are PT-141 and setmelanotide dosed in research?
The research range for PT-141 is 0.5–2 mg, with a 1.25 mg starting dose. Studied in research — not a recommendation. FDA-approved as Vyleesi: 1.75 mg SubQ as needed, at least 45 minutes before sex (at most once a day, 8 times a month), for premenopausal women with acquired, generalized low sexual desire (HSDD). The FDA label range for setmelanotide is 0.5–3 mg, with a 0.5 mg starting dose.
What are the common side effects of PT-141 and setmelanotide?
For PT-141, the library lists: nausea (most common), flushing, blood pressure elevation, spontaneous erections, hyperpigmentation with frequent use. For setmelanotide: skin darkening, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, low mood, spontaneous erections.